Takaya Uno1,2,3, Kyoichi Wada1,3, Sachi Matsuda1, Yuka Terada1, Akira Oita1, Atsushi Kawase4, Mitsutaka Takada5,6. 1. Department of Pharmacy, National Cerebral and Cardiovascular Center, Suita, Japan. 2. Division of Clinical Drug Informatics, Faculty of Pharmacy, Kindai University, Higashi-osaka, Japan. 3. Division of Cardiovascular Drugs, Therapy, Kindai University Graduate School of Pharmacy, Higashi-osaka, Japan. 4. Department of Pharmacy, Faculty of Pharmacy, Kindai University, Higashi-osaka, Japan. 5. Division of Clinical Drug Informatics, Faculty of Pharmacy, Kindai University, Higashi-osaka, Japan. takada@phar.kindai.ac.jp. 6. Division of Cardiovascular Drugs, Therapy, Kindai University Graduate School of Pharmacy, Higashi-osaka, Japan. takada@phar.kindai.ac.jp.
Abstract
BACKGROUND AND OBJECTIVE: Tacrolimus, a major immunosuppressant used after transplantation, is associated with large interindividual variation involving genetic polymorphisms in metabolic processes. A common variant of the cytochrome P450 (CYP) 3A5 gene, CYP3A5*3, affects blood concentrations of tacrolimus. However, tacrolimus pharmacokinetics at the early stage of transplantation have not been adequately studied in heart transplantation. We retrospectively examined the impact of the CYP3A5 genotype on tacrolimus pharmacokinetics at the early stage of heart transplantation. METHODS: The tacrolimus pharmacokinetic profile was obtained from 65 patients during the first 5 weeks after heart transplantation. Differences in the patients' characteristics and tacrolimus pharmacokinetic parameters between the CYP3A5 expresser (*1/*1 or *1/*3 genotypes) and non-expresser (*3/*3 genotype) groups were assessed by the Chi-square test, Student's t test, or Mann-Whitney U test. RESULTS: The CYP3A5 *1/*1, *1/*3, and *3/*3 genotypes were detected in 5, 22, and 38 patients, respectively. All patients started clotrimazole therapy approximately 1 week after starting tacrolimus. Apparent clearance and dose/weight to reach the target trough concentration (C0) were significantly higher in the expresser group than in the non-expresser group (0.32 vs. 0.19 L/h/kg, p = 0.0003; 0.052 vs. 0.034 mg/kg/day, p = 0.0002); there were no significant differences in the area under the concentration-time curve from 0 to 12 h (AUC0-12) and concentrations at any sampling time point between the two groups. CONCLUSION: Similar concentration-time curves for tacrolimus were obtained in the expresser and non-expresser groups by dose adjustment based on therapeutic drug monitoring. These results demonstrate the importance of the CYP3A5 genotype in tacrolimus dose optimization based on therapeutic drug monitoring after heart transplantation.
BACKGROUND AND OBJECTIVE:Tacrolimus, a major immunosuppressant used after transplantation, is associated with large interindividual variation involving genetic polymorphisms in metabolic processes. A common variant of the cytochrome P450 (CYP) 3A5 gene, CYP3A5*3, affects blood concentrations of tacrolimus. However, tacrolimus pharmacokinetics at the early stage of transplantation have not been adequately studied in heart transplantation. We retrospectively examined the impact of the CYP3A5 genotype on tacrolimus pharmacokinetics at the early stage of heart transplantation. METHODS: The tacrolimus pharmacokinetic profile was obtained from 65 patients during the first 5 weeks after heart transplantation. Differences in the patients' characteristics and tacrolimus pharmacokinetic parameters between the CYP3A5 expresser (*1/*1 or *1/*3 genotypes) and non-expresser (*3/*3 genotype) groups were assessed by the Chi-square test, Student's t test, or Mann-Whitney U test. RESULTS: The CYP3A5 *1/*1, *1/*3, and *3/*3 genotypes were detected in 5, 22, and 38 patients, respectively. All patients started clotrimazole therapy approximately 1 week after starting tacrolimus. Apparent clearance and dose/weight to reach the target trough concentration (C0) were significantly higher in the expresser group than in the non-expresser group (0.32 vs. 0.19 L/h/kg, p = 0.0003; 0.052 vs. 0.034 mg/kg/day, p = 0.0002); there were no significant differences in the area under the concentration-time curve from 0 to 12 h (AUC0-12) and concentrations at any sampling time point between the two groups. CONCLUSION: Similar concentration-time curves for tacrolimus were obtained in the expresser and non-expresser groups by dose adjustment based on therapeutic drug monitoring. These results demonstrate the importance of the CYP3A5 genotype in tacrolimus dose optimization based on therapeutic drug monitoring after heart transplantation.
Authors: Violette Gijsen; Seema Mital; Ron H van Schaik; Offie P Soldin; Steven J Soldin; Ilse P van der Heiden; Irena Nulman; Gideon Koren; Saskia N de Wildt Journal: J Heart Lung Transplant Date: 2011-09-17 Impact factor: 10.247
Authors: Shwetal Lalan; Susan Abdel-Rahman; Andrea Gaedigk; J Steven Leeder; Bradley A Warady; Hongying Dai; Douglas Blowey Journal: Pediatr Nephrol Date: 2014-05-30 Impact factor: 3.714
Authors: Jessica van Setten; Evangeline G Warmerdam; Olivier Q Groot; Nicolaas de Jonge; Brendan Keating; Folkert W Asselbergs Journal: Transplant Direct Date: 2019-01-21
Authors: Maaike A Sikma; Claudine C Hunault; Erik M Van Maarseveen; Alwin D R Huitema; Ed A Van de Graaf; Johannes H Kirkels; Marianne C Verhaar; Jan C Grutters; Jozef Kesecioglu; Dylan W De Lange Journal: Eur J Drug Metab Pharmacokinet Date: 2020-02 Impact factor: 2.441